Literature DB >> 22440266

Does extended prostate needle biopsy improve the concordance of Gleason scores between biopsy and prostatectomy in the Taiwanese population?

Ching-Wei Yang1, Tzu-Ping Lin, Yi-Hsiu Huang, Hsiao-Jen Chung, Junne-Yih Kuo, William J S Huang, Howard H H Wu, Yen-Hwa Chang, Alex T L Lin, Kuang-Kuo Chen.   

Abstract

BACKGROUND: Discordance between the Gleason scores of prostate needle biopsies and radical prostatectomy specimens has been reported by several investigators. We conducted this study to determine if increasing the number of prostate needle biopsies in patients with prostate cancer improves the accuracy of Gleason scores in the Taiwanese population.
METHODS: Between March 2000 and September 2009, 281 patients underwent radical prostatectomy at Taipei Veterans General Hospital. All of these patients had prostate cancer that was diagnosed and graded either by extended needle biopsy (121 patients, ≥ 10 cores/patient, range: 10-13, median: 12) or by traditional sextant transrectal biopsy (160 patients, <10 cores/patient, range: 6-9, median: 6). We analyzed the patients' Gleason scores of their biopsies and radical prostatectomy specimens.
RESULTS: The concordance rate, defined as similarity between the Gleason score of a patient's biopsy and prostatectomy specimens, was 57.9% in the extended biopsy group and 45.6% in the nonextended biopsy group (χ(2) test: p = 0.042). The primary Gleason pattern was accurately predicted by extended needle biopsy in 81% of cases (98/121 cases), higher than the 70% accuracy rate of the nonextended biopsies (112/160 cases, p = 0.036). Undergrading was found in 43/121 cases (32%) and 63/160 cases (39.4%) (p = 0.511). However, overgrading was found in 8/121 cases (6.6%) and in 24/160 cases (15.0%) (p = 0.028) by extended and nonextended biopsies, respectively. Forty-seven (16.7%) of those patients who fit the criteria of active surveillance were upgraded to a Gleason score >7 after radical prostatectomy.
CONCLUSION: The addition of an extended transrectal needle biopsy increases the accuracy of the Gleason score for predicting the final prostate cancer grade in the Taiwanese population. Copyright Â
© 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22440266     DOI: 10.1016/j.jcma.2012.02.001

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  5 in total

1.  PathAL: An Active Learning Framework for Histopathology Image Analysis.

Authors:  Wenyuan Li; Jiayun Li; Zichen Wang; Jennifer Polson; Anthony E Sisk; Dipti P Sajed; William Speier; Corey W Arnold
Journal:  IEEE Trans Med Imaging       Date:  2022-05-02       Impact factor: 11.037

2.  Gleason group concordance between biopsy and radical prostatectomy specimens: A cohort study from Prostate Cancer Outcome Registry - Victoria.

Authors:  Sue M Evans; Varuni Patabendi Bandarage; Caroline Kronborg; Arul Earnest; Jeremy Millar; David Clouston
Journal:  Prostate Int       Date:  2016-08-03

3.  Extent and predictors of grade upgrading and downgrading in an Australian cohort according to the new prostate cancer grade groupings.

Authors:  Kerri Beckmann; Michael O'Callaghan; Andrew Vincent; Penelope Cohen; Martin Borg; David Roder; Sue Evans; Jeremy Millar; Kim Moretti
Journal:  Asian J Urol       Date:  2019-03-07

4.  Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions.

Authors:  Nishi Karunasinghe; Tsion Zewdu Minas; Bo-Ying Bao; Arier Lee; Alice Wang; Shuotun Zhu; Jonathan Masters; Megan Goudie; Shu-Pin Huang; Frank J Jenkins; Lynnette R Ferguson
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

5.  Prediction of a positive surgical margin and biochemical recurrence after robot-assisted radical prostatectomy.

Authors:  Ching-Wei Yang; Hsiao-Hsien Wang; Mohamed Fayez Hassouna; Manish Chand; William J S Huang; Hsiao-Jen Chung
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.